A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer.

For advanced pancreatic cancer, many regimens have been compared with gemcitabine (G) as the standard arm in randomized controlled trials. Few regimens have been directly compared with each other in randomized controlled trials and the relative efficacy and safety among them remains unclear.